Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area

Hassan Mir(University of Ottawa), Darryl P. Leong(Population Health Research Institute), Ahmad Alshatti(Hamilton Health Sciences), Muhammad Mustafa Alhussein(Hamilton Health Sciences), Nicholas Valettas(Hamilton General Hospital), Vidhya Nair(University Health Network), Hussain Alzayer(Hamilton Health Sciences), Som D. Mukherjee(Juravinski Cancer Centre), Sulaiman Alrashidi(Hamilton Health Sciences)
Canadian Journal of Cardiology
March 28, 2018
10.1016/j.cjca.2018.03.012
Cited by 127

Related Papers

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study
|The Lancet|2019|2k
Reducing the Global Burden of Cardiovascular Disease, Part 1
|Circulation Research|2017|1.1k
Cardiac tumours: diagnosis and management
|The Lancet Oncology|2005|848
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Oncology|2020|502